Leap granted fast track designation for mAb to treat gastric cancers

By The Science Advisory Board staff writers

September 24, 2020 -- Leap Therapeutics said that its DKN-01 monoclonal antibody (mAb) has received fast track designation by the U.S. Food and Drug Administration (FDA) for treatment of gastric and gastroesophageal junction (G/GEJ) adenocarcinomas.

The humanized mAb is designed for treatment of G/GEJ adenocarcinoma whose tumors express high Dickkopf-1 protein (DKK1), following disease progression on or after prior fluoropyrimidine- and platinum- containing chemotherapy and if appropriate, HER2/neu-targeted therapy. DKN-01 binds to and blocks the activity DKK1, a modulator of Wnt/Beta-catenin signaling.

DKN-01, which is currently being evaluated in clinical trials for gastroesophageal, gynecologic, hepatobiliary, and prostate cancers, has also received an "orphan drug" designation by the FDA for treatment of GE/GEJ cancer, Leap said.

Copyright © 2020 scienceboard.net

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.